Trials & Filings

Bayer PAH/CTEPH Drug Approved

Adempas marks first-in-class treatment

By: Gil Roth

President, Pharma & Biopharma Outsourcing Association

The FDA has approved Bayer HealthCare‘s NDA for Adempas (riociguat) tablets for both the treatment of adults with persistent/recurrent chronic thromboembolic pulmonary hypertension (CTEPH) after surgical treatment or inoperable CTEPH to improve exercise capacity and WHO functional class, and the treatment of adults with pulmonary arterial hypertension (PAH) (WHO Group 1) to improve exercise capacity, improve WHO functional class and delay clinical worsening. In PAH, efficacy was shown in ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters